Amin Karim, MD
Cardiovascular Disease · Houston, TXNPI 1982690988
Payments from drug & device makers
Across 268 payments — averaging $3182.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$373K
- E.r. Squibb & Sons, L.L.C.$104K
- AstraZeneca$102K
- Novartis$88K
- Pfizer$69K
- Boehringer Ingelheim$41K
- plus $77K from 23 others
Across 10 payments — averaging $2991.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vifor (international) Ltd.$29K
- Eli Lilly$917
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 38 | $372,663 |
| E.r. Squibb & Sons, L.L.C. | 8 | $103,918 |
| AstraZeneca | 8 | $102,190 |
| Novartis | 11 | $87,524 |
| Pfizer | 42 | $69,486 |
| Boehringer Ingelheim | 17 | $40,611 |
| Boehringer Ingelheim International GmbH | 61 | $33,186 |
| Alnylam Pharmaceuticals Inc. | 2 | $16,051 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 7 | $15,554 |
| Novo Nordisk AS | 33 | $3,715 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $3,250 |
| Eisai Inc. | 2 | $1,676 |
| Vifor (international) Ltd. | 1 | $800 |
| Janssen Research & Development, LLC | 1 | $500 |
| Amarin Pharma, Inc. | 5 | $457 |
| Boehringer Ingelheim France S.a.s. | 2 | $281 |
| Boehringer Ingelheim Canada Ltd.ltee | 2 | $281 |
| Johnson & Johnson | 9 | $167 |
| Eli Lilly | 1 | $141 |
| Merck | 6 | $114 |
| Novo Nordisk | 2 | $112 |
| Biosense Webster, Inc. | 1 | $91 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Sanofi | 1 | $25 |
| Boston Scientific | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Bardy Diagnostics, Inc. | 1 | $18 |
| Altathera Pharmaceuticals LLC | 1 | $17 |
How this compares
$852,921 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Houston
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- James FeldmanHouston$3.1M
- Aditya SamalHouston$2.6M
- Pranav LoyalkaHouston$2.4M
- Anwar AhmadHouston$1.4M
- Reynolds DelgadoHouston$1.1M
- Richard SmallingHouston$908K
- Stephen LittleHouston$806K
- Joggy GeorgeHouston$634K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.